A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA

Nephrology Dialysis Transplantation

Volumn 23, Issue 4, 2008, Pages 1216-1223

  Palmer, Andrew J ^a   Valentine, William J ^a   Chen, Roland ^b   Mehin, Nazanin ^c   Gabriel, Sylvie ^c   Bregman, Bruno ^b   Rodby, Roger A ^d  

^a IQVIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c SANOFI   (France)

^d Bristol Myers Squibb ^*  (United States)

Author keywords

Angiotensin receptor blocker; Cost effectiveness; Costs; Hypertension; Nephropathy; Type 2 diabetes mellitus

Indexed keywords

IRBESARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; SCREENING TEST; UNITED STATES; AGE DISTRIBUTION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; FEMALE; MALE; MASS SCREENING; MIDDLE AGED; MORBIDITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SURVIVAL RATE;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DISEASE-FREE SURVIVAL; FEMALE; HEALTH CARE COSTS; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INCIDENCE; KIDNEY FAILURE, CHRONIC; LIFE EXPECTANCY; MALE; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; MORBIDITY; PROGNOSIS; QUALITY OF LIFE; RENAL INSUFFICIENCY; SURVIVAL RATE; UNITED STATES;

EID: 42949118875     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn082     Document Type: Article

References (40)

1. Smitten A, Rodby RA, Chen RS. The increasing prevalence of microalbuminuria in the United States: data from the National Health and Nutrition Examination Survey (NHANES) III (1988-1994) and NHANES 1999-2000. J Am Soc Nephrol 2003; 14(Suppl.): 682 (Abstract)
2. Ritz E, Rychlik I, Locatelli F et al. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808
3. Vora JP, Ibrahim HA, Bakris GL. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens 2000; 14: 667-685
4. U.S. Renal Data System. Atlas of End-Stage Renal Disease in the United States. USRDS 2001 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2001
5. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14(Suppl 5): S1-S85
6. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413-1418
7. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426
8. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232
9. Molitch ME, DeFronzo RA, Franz MJ et al. Nephropathy in diabetes. Diabetes Care 2004; 27(Suppl 1): S79-S83
10. Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129(1 Suppl): 169S-173S
11. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 910-912
12. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
13. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
14. Palmer AJ, Annemans L, Roze S et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 2004; 27: 1897-1903
15. European Society of Hypertension. European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053
16. Sigwalt M, Whyte JL, Saunders S et al. Persons with hypertension and Type 2 diabetes are not receiving care per ADA Diabetic Nephropathy Guidelines. J Am Soc Nephrol 2004; 15(Suppl): 573 (Abstract)
17. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951
18. Palmer AJ, Annemans L, Roze S et al. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian, and French settings. Nephrol Dial Transplant 2003; 18: 2059-2066
19. World Health Organization. Life tables for 191 countries. World mortality in 2000. http://www.who.org
20. Saydah SH, Loria CM, Eberhardt MS et al. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 2001; 24: 447-453
21. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393
22. Stehouwer CD, Gall MA, Twisk JW et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51: 1157-1165
23. Rodby RA, Chiou CF, Borenstein J et al. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003; 25: 2103-2119
24. Age distribution of oral antidiabetics by prescription year ending. 2000; www.ims-global.com
25. McIntosh A, Hutchinson A, Marshall T et al. Clinical Guidelines and Evidence Review for Type 2 Diabetes. Renal Disease: Prevention and Early Management. Sheffield: School of Health and Related Research, University of Sheffield, 2002
26. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17: 479-500
27. Drug Topics Red Book. Montvale, NJ: Medical Economics Company, 2000
28. Brown GC, Brown MM, Sharma S et al. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications 2000; 14: 18-24
29. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38: 583-637
30. Weinstein MC, Siegel JE, Gold MR et al. Recommendations of the panel on cost-effectiveness in health and medicine [see comments]. JAMA 1996; 276: 1253-1258
31. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002; 23: 377-401
32. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996; 5: 513-524
33. De Vecchi AF, Dratwa M, Wiedemann ME. Healthcare systems and end-stage renal disease (ESRD) therapies - an international review: costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant 1999; 14(Suppl 6): 31-41
34. Ismail N, Becker B, Strzelczyk P et al. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55: 1-28
35. Borch-Johnsen K, Wenzel H, Viberti GC et al. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 1993; 306: 1722-1725
36. Bennett PH, Haffner S, Kasiske BL et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995; 25: 107-112
37. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 1995; 311: 1595-1599
38. Kiberd BA, Jindal KK. Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation. Am J Kidney Dis 1998; 31: 49-54
39. Palmer AJ, Weiss C, Sendi PP et al. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 2000; 43: 13-26
40. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999; 131: 660-667